Modification of the Local Abnormal Ventricular Activity Only

Substrate Based Modification in Ventricular Tachycardia: Ablation of the Local Abnormal Ventricular Activity Only

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05331716

Acronym

LAVAONLY

Enrollment

Registered

2022-04-18

Start date

2019-01-01

Completion date

2021-12-31

Last updated

2022-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventricular Tachycardia

Keywords

local abnormal ventricular activity, substrate modification, electrophysiology, LAVA, decremental

Brief summary

Local abnormal ventricular activity (LAVA) is composed of high-frequency, mainly low voltage signals that represent near-field signals from slow-conducting tissue and thus potential VT isthmuses. The identification of LAVA potentials and their modification have usually been a complimentary component of the substrate-based modification of scar related ventricular arrhtyhmias. With better identification through technical solutions and improved algorithms, LAVA modification may be feasible for treatment in therapy refractory VT.

Detailed description

As of 2019 we started LAVA modification only in a subset of patients with therapy refractory ventricular tachycardia. The cohort icludes 55% patient with ischemic cardiomyopathy and 45% with dilated cardiomyopathy. 80% are ICD recipients. These patients were now retrospectively analysed in depth. The endpoint is time to relapse of ventricular tachycardia or ICD shock or death due to malignant arrhythmia. We evaluated all patients we treated accordingly from March 2019 through October 2020. No patient was excluded.

Interventions

PROCEDURECardiac ablation therapy

In a subset of patients with known therapy refractory arrhythmia sole LAVA modification is fashioned

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

therapy refractory ventricular arrhythmia

Exclusion criteria

none

Design outcomes

Primary

Measure	Time frame	Description
VT	12 months	occurrence/documentation of ventricular arrhythmia in participant after substrate modification during follow-up period (either Holter ECG or defibrillator interogation or ILR/ICM or electrophysiology study)
appropriate therapy delivered by defibrillator (ICD)	12 months	appropriate therapy (shock, ATP) delivered by ICD in participants during follow-up period
death	12 months	patient succumbed due to malignant ventricular arrhythmia or therapy

Secondary

Measure	Time frame	Description
death any cause	36 months	death any cause during observation period

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026